SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Fate Therapeutics Reports FDA Clearance For Investigational New Drug Application For FT538, CRISPR-Edited, iPSC-Derived Cell Therapy

Benzinga · 05/20/2020 12:21